Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Risdiplam reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Risdiplam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Evrysdi

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Evrysdi

    Risdiplam

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Evrysdi

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Roche

    Risdiplam

    Main Therapeutic Indication : Neurology

    Currency : USD

    2021 Revenue in Millions : 648

    2020 Revenue in Millions : 58

    Growth (%) : 995

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Evrysdi

    Risdiplam

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Evrysdi

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Roche

    Risdiplam

    Main Therapeutic Indication : Neurology

    Currency : USD

    2022 Revenue in Millions : 1,223

    2021 Revenue in Millions : 648

    Growth (%) : 89

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Evrysdi

    Risdiplam

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Evrysdi

    Switzerland
    arrow
    AAPS 2024
    Not Confirmed

    Roche

    Risdiplam

    Main Therapeutic Indication : Neurology

    Currency : USD

    2023 Revenue in Millions : 1,646

    2022 Revenue in Millions : 1,223

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF